Key terms
About ADVM
Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company that engages in the development of gene therapies for ocular and rare diseases. The company was founded by Mark S. Blumenkranz, Thomas W. Chalberg, Jr., Mitchell H. Finer, and Steven Daniel Schwartz on July 17, 2006 and is headquartered in Redwood City, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ADVM news
Today
6:45am ET
Buy Rating Affirmed for Adverum’s Gene Therapy on Promising Interim Phase 2 Results and Potential Standard of Care Shift in nAMD Treatment
Today
6:39am ET
Adverum Biotechnologies (ADVM) Receives a New Rating from RBC Capital
Apr 30
6:20am ET
Analysts Are Bullish on Top Healthcare Stocks: Abbott Labs (ABT), Iterum Therapeutics (ITRM)
Apr 30
6:03am ET
Adverum Biotechnologies initiated with a Buy at H.C. Wainwright
Apr 30
4:55am ET
Adverum Biotechnologies management to meet with Truist
Apr 29
6:49am ET
Adverum Biotechnologies price target lowered to $22 from $40 at Mizuho
Apr 26
7:34am ET
Adverum Biotechnologies management to meet with Truist
Mar 27
9:50pm ET
Analysts Are Neutral on These Healthcare Stocks: SAGE Therapeutics (SAGE), Adverum Biotechnologies (ADVM)
Mar 25
10:30pm ET
Wall Street Analysts Are Bullish on Top Healthcare Picks
Mar 21
5:26pm ET
Adverum Biotechnologies files $200M mixed securities shelf
Mar 21
2:46am ET
Positive Outlook for Adverum Biotechnologies with Upcoming Ixo-vec Milestones and Strong Financial Position
Mar 20
7:50pm ET
Adverum Biotechnologies trading halted, news pending
Mar 20
2:00am ET
Brexit Uncertainty: Navigating New Risks and Regulatory Hurdles for Adverum Biotechnologies
Mar 19
7:20am ET
Adverum Biotechnologies price target lowered to $2 from $3 at RBC Capital
Mar 19
6:45am ET
Adverum Biotechnologies (ADVM) Initiated with a Hold at RBC Capital
Mar 18
5:55pm ET
Adverum Biotechnologies (ADVM) Receives a Buy from TD Cowen
Mar 18
4:13pm ET
Adverum Biotechnologies reports Q4 EPS (23c), consensus (34c)
Mar 04
4:42pm ET
Adverum Biotechnologies files to sell 106.48M shares of common stock for holders
No recent press releases are available for ADVM
ADVM Financials
Key terms
Ad Feedback
ADVM Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ADVM Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range